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Abstract  14 
There is currently no vaccine against schistosomiasis. With few Schistosoma vaccine candidates in 15 
clinical trials, unexplored antigens from the vulnerable schistosomulum should be considered as possible 16 
vaccine candidates. In addition, we suggest developing synthetic vesicles as a new delivery vehicle and 17 
adjuvant for immunoprophylactic schistosomula vaccine candidates. 18 
Keywords: Schistosoma, schistosomula, synthetic vesicles, vaccine candidates, delivery, adjuvant  19 
It is Time to Think Elimination  20 
Schistosomiasis is one of the most prevalent parasitic diseases worldwide. Treatment of schistosomiasis 21 
in populations at risk with a single dose of praziquantel annually has not prevented transmission of 22 
Schistosoma and subsequently reinfection is common in endemic areas. The World Health Organisation 23 
(WHO) reported that 219 million people worldwide needed preventative treatment against 24 
schistosomiasis in 2015. Of those who required treatment, less than one third received it through mass 25 
drug administration (MDA) programmes (1). Even more disconcerting is that modelling studies suggest 26 
that MDA will only reduce the prevalence of schistosomiasis if more than 70% of communities 27 
participate and the MDA is conducted annually (2). A drug-based strategy alone therefore may not move 28 
national schistosomiasis programs of low to middle income countries from morbidity control towards 29 
elimination (3). Other interventions, working alongside MDA, such as vaccination, could effectively 30 
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prevent reinfection, and thus eliminate schistosomiasis. Vaccination with radiation-attenuated cercariae 31 
protects murine and non-human primate models against challenges with schistosomes. However, using 32 
radiation-attenuated cercariae in human trials is impractical because it is difficult to produce under good 33 
manufacturing practice (GMP), and delivery of the vaccine under liquid nitrogen presents considerable 34 
logistical challenges. As a consequence, recombinant antigens that can be easily produced are being 35 
considered as potential subunit vaccine candidates (Reviewed in (4)). Some of these vaccine candidates 36 
are efficacious against challenge infection in animal models, but show low immunogenicity as purified 37 
single antigens when tested further in human preclinical tests. Therefore, we suggest two approaches to 38 
improve the immunogenicity of Schistosoma vaccine antigens. Firstly, multiple, and not single, antigens 39 
should be used (both EV and non-EV encoded) in the development of schistosomiasis vaccine. Secondly, 40 
we consider synthetic vesicles as a proof of concept antigen delivery and adjuvant system. Schistosoma-41 
shed vesicles have been recently identified (5, 6), but whether we can design synthetic stimulatory 42 
versions of these vesicles to deliver Schistosoma vaccine targets is a question yet to be addressed. This 43 
forum article examines the potential of using synthetic vesicles as adjuvant and delivery vehicle 44 
containing multiple schistosomula vaccine candidates.  45 
Targeting Schistosomula Antigens as Vaccine Candidates  46 
The schistosomulum is the transition phase between a free-living non-feeding cercaria in fresh water 47 
and the parasitic blood fluke in the mammalian host. When cercariae penetrate human skin, they 48 
transform into the skin-stage schistosomula (Fig. 1). The skin-stage schistosomula up regulate specific 49 
genes during transformation to facilitate invasion and to survive the hostile host immune response (7). 50 
The schistosomula also develop a new double lipid bilayer outer membrane covering the tegument that 51 
facilitates survival within the host. Just as the new coat develops, the early post-penetration 52 
schistosomulum is vulnerable to host immune-mediated attack (8). The late phase schistosomulum is 53 
less susceptible to both eosinophil and macrophage mediated cytotoxicity when it develops towards 54 
adulthood. Early schistosomulum antigens are therefore possible candidates to develop a prophylactic 55 
vaccine against human schistosome infections. However, there are few current efforts to identify and 56 
prioritise schistosomula antigens for a novel vaccine. One such initiative was TheSchistoVac consortium 57 
that targeted antigens highly expressed by the skin schistosomula for vaccine development 58 
(http://www.theschistovac.eu/). The work done provides a template for future targeted (stage-specific) 59 
vaccine development.  60 
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Schistosomes are complex multicellular organisms, and this may partly explain why current vaccines 61 
composed of a single antigen are not capable of inducing long-lived protective immunity. We propose 62 
multiple antigen preparations to target different aspects of the early stage schistosomula ranging from 63 
tegument formation and turnover to metabolite (glucose) uptake. In fact, the multivalent chimeric 64 
schistosomiasis vaccine of SmTSP-2 and Sm29 induces more robust immune responses compared to 65 
single antigen preparations in mice (9). Although identifying new antigens based on the schistosomulum 66 
is a critical step, combining new and existing antigens as a multiple vaccine preparation is, we believe, a 67 
necessary step in designing the next generation of vaccine to a complex, multicellular organism. We 68 
would suggest both non-EV (to target the schistosomula) and EV encoded (to target secreted EVs) 69 
antigens. Finally, the multiple antigen vaccine will require new tools such as synthetic vesicles to be 70 
delivered to immune cells.  71 
Synthetic Vesicles to Deliver Schistosoma Vaccine Candidates 72 
Schistosomes release excreted/secreted (E/S) products to survive the hostile host immune system. 73 
Among these products characterised to date are Schistosoma-shed vesicles known as extracellular 74 
vesicles (EVs) (5, 6), spherical structures encapsulated by a lipid bilayer and shown to be responsible for 75 
intercellular communication (10). The major subsets of EVs are exosomes, microvesicles and apoptotic 76 
bodies. EVs are classified based on their biogenesis, their size, and what surface markers they express. 77 
Of importance is that Schistosoma EVs (derived from both schistosomula and adult worms) contain 78 
potential vaccine candidates including SmTSP-2 and Sm29 (5, 6).  79 
We suggest packaging schistosome vaccine antigens in synthetic vesicles because naturally occurring S. 80 
mansoni EVs may contain inhibitory biological material such as miRNAs and tsRNAs (6). Packaging 81 
parasite antigens into vesicles will improve their antigenicity compared to using the antigens directly for 82 
vaccination (11). Another advantage of utilizing synthetic vesicles is that they are free of host proteins 83 
that have been described in EVs of other parasites such as Echinostoma caproni and Fasciola hepatica 84 
(12). The proof-of-concept for manufacturing synthetic vesicles already exists with other lipid molecules 85 
such as virus like particles (VLPs) and outer membrane vesicles (OMVs). The pros and cons of antigen 86 
delivery using synthetic vesicles are summarised in Table 1. We suggest it is now time to take this 87 
technology forward and target the schistosome. 88 
Vaccine candidates within vesicles are also effectively protected from degradation as they move through 89 
body fluids, improving their stability within host. For synthetic vesicles to work as adjuvants, additional 90 
ligands that target receptors on antigen presenting cells such as pathogen recognition receptors on 91 
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dendritic cells could be added on the vesicle surface using glycosylphosphatidylinositol (GPI) anchors for 92 
robust cellular responses. With appropriate thought given to the incorporation of membrane-embedded 93 
glycoprotein ligands or receptors, targeting specific immunological cells could be engineered and 94 
achieved. In addition to targeting the actual schistosomula, immune responses induced by synthetic 95 
vesicles (to EV encoded antigens) will also target and neutralise Schistosoma EVs, decreasing the ability 96 
of the schistosomula to dampen immune responses and make the environment less suitable for survival. 97 
All in all, immune responses to multiple antigen preparations from the early phase of the 98 
schistosomulum packaged in synthetic vesicles may prevent development of the adult schistosomes and 99 
subsequently the laying of eggs that cause pathology associated with schistosomiasis.  100 
Conclusion  101 
Although schistosomiasis is treatable, reinfections are common in endemic areas. It is widely 102 
acknowledged that a vaccine used alongside chemotherapy would control and possibly eliminate 103 
schistosomiasis. We have suggested using synthetic vesicles that are preloaded with multiple 104 
schistosomula antigens to elicit protective, skin-stage host responses as a next-generation anti-105 
schistosomal vaccine. As we move towards 2025, the year WHO set to eliminate schistosomiasis 106 
globally, these and other novel approaches are required to develop vaccines. 107 
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Figure 1. Migration of schistosomula through the host skin. 1. Cercaria is attracted to human skin. 2 153 
Cercaria burrows through the skin and detaches the bifurcated tail to form a schistosomulum. 3 154 
Schistosomulum release excretion/secretion (ES) products including extracellular vesicles (EVs) that 155 
interact with resident Langerhans cells, which migrate to skin draining lymph nodes to initiate adaptive 156 
immune responses. 4 The schistosomulum moves towards the basement membrane that temporarily 157 
halts their migration. 5 Once in the dermis, the schistosomulum is vulnerable to antibody-mediated 158 
killing by granulocytes. 6 Schistosome-induced cytokines activate more phagocytes and polarize the 159 
immune response towards inflammatory responses. 7 Schistosomulum penetrates dermal veins and 160 
 6 
migrates to the lungs. 8 Schistosomulum is coated with host proteins as an immune evasion mechanism. 161 
The figures were adapted and modified from Servier Medical Art (http://smart.servier.com/). 162 
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Table 1. Pros and cons of antigen delivery via synthetic vesicles 166 
Advantages EV and non-EV antigens target both schistosomula and EVs increasing 
immunogenicity 
 Antigen presenting cells can be targeted by displaying specific ligands on 
outer surface of synthetic vesicles using GPI anchors 
 Adding molecules that activate antigen presenting cells means that 
synthetic vesicles are not just antigen delivery vehicles, but also an 
adjuvant as well 
 Synthetic vesicles exhibit natural EV properties such as stability and 
resistance to enzymatic degradation in body fluids 
 Naturally occurring EV cargo, such as miRNA, with inhibitory properties 
are avoided in synthetic vesicles 
 Synthetic vesicles lack host proteins, a potential mechanism for 
decreasing immunogenicity  
  
Disadvantages Expensive to manufacture 
 
 Risk of reactogenicity associated with synthetic materials may lead to 
adverse effects in humans 
 Extensive regulatory requirements are expected for human use license 
 
 167 
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